Loading
What is happening and how strong the evidence is: dates, congress readouts, approvals, failures, resistance, and the supply chain behind the drugs.
The freshest signals in cancer: new papers, trial results, approvals and law, one feed updated with every build, with RSS and JSON.
Where the evidence is published: scope, access model and the key papers each venue carried.
The papers that changed practice, each explained: what it found, what it means, what to be careful about.
Every trial result as people out of 100, medians explained, surrogate endpoints flagged.
Every trial design as a card: when to use it, a worked example from the corpus and its main risk, with a plain-English guide to which design fits your question.
Where NCCN, ESMO, NICE and ASCO agree and disagree, and what changed between guideline versions.
Every hazard ratio in the trial corpus on one log axis; filter by cancer, setting and endpoint.
Every trial ranked by evidence strength, endpoints as people out of 100.
Regulatory decisions, expected readouts, filings and deal closings by company, with a calendar feed.
Who bought or licensed what, for how much, and where assets flow between regions.
When each product loses patent or regulatory exclusivity, and the biosimilars and generics coming.
Assets by phase for any target, modality or cancer, and how crowded each target is.
Every medicine taken apart into its modules, and the grid of every combination: approved, in development, tried and stopped with the reason, or never tried.
One hub per shape of medicine (ADC, radioligand, CAR-T, bispecific, degrader and the rest): how it works, approved medicines, phase 3, parts, companies, trials, side effects, resistance, papers, roadmaps, ideas and manufacturing, each section naming its records.
Incidence times prevalence times setting share, every input linked, as a range.
Decisions, readouts, advisory committees, congresses.
ASCO, ESMO, AACR, ASCO GU, sourced item by item.
What did not work, and the lesson.
Escape routes per drug class and the countermeasures.
Escape routes with no countermeasure, or only preclinical ones: the drug-design opportunities.
Every assay and its cut-off: PD-L1 CPS, HER2-low, MSI, TMB, HRD and the multi-gene panels, linked to the drugs they gate.
bioRxiv and medRxiv preprints of the last 90 days per target, product and technology, and which have since been published.
The chemistry inside ADCs.
Every dated filing, approval, CRL, and label change.
The statutes, regulations and court rulings that decide how cancer drugs are approved, paid for and tested, and how data and genes are protected, by jurisdiction and theme.
Medicare Part B or D, prior authorisation, list prices and assistance programmes for every approved product.
NICE, Cancer Drugs Fund and SMC decisions for every approved product, and how NHS cancer care works.
US insurers and plan types ranked by one published metric at a time, UK NHS entitlement against private medical insurance, and how ten countries pay for cancer drugs.
Each cost driver paired with what is being done and the ideas that could do more: biosimilars, negotiation, dose optimisation, shorter courses, parity, prior authorisation.
NICE, SMC, G-BA and PBAC verdicts per product and country, with dates and links to the appraisal.
Five-year relative survival by cancer and stage from SEER, with the period and caveats.
Which products are approved in the US, EU, UK, Japan, China and Australia, and which are missing where.
Fastest-growing topics in the literature, refreshed weekly from Europe PMC.
What the leading journals, regulators and news sources are saying this month.
Grade 3+ adverse events across products of the same class.
Lu-177, Ac-225, Pb-212 and who makes them.
The state of the war on cancer, year by year, generated from the corpus.
What changed in OnCo, and when.
When each automated feed last ran, what is stale, and the incident log.
How old is too old for each kind of record, by review track, and what is past due.
What changed on which record, field by field, from the git history.
Staleness, contradictions, and registry mismatches, recomputed each build.
Every factual correction, what was wrong and how it was found.